For example, AMPK is also activated by KRAS overexpression or PTEN knockdown in GBM (Chhipa et al., 2018), and KRAS mutation or amplification is found in approximately 3% of GBM, while PTEN alteration is in approximately 40% of GBM, including in roughly 50% of EGFR-amplified cases (Brennan et al., 2013). This evidence concerns the gene PTEN and glioblastoma.